ABOUT THE NEED TO IMPROVE IMMUNIZATION AGAINST THE WHOOPING COUGH

The aim of the study was to identify current epidemiological patterns of pertussis and to assess the need to improve immunization against this infection. Methods. A comparative retrospective epidemiological analysis of pertussis incidence in Russian population, in several European countries and in certain social and age groups has been performed considering vaccination coverage, immunization strategy, and diagnostic tests. A comparative analysis of gen eral and agerelated morbidity of and mortality from infectious and respiratory diseases in Russian population and in some European countries has also been performed. Data on morbidity, mortality and vaccination were obtained from databases of WHO and the Federal State Statistic Service of Russian Federation. Results. The epidemiological situation evolving pertussis is not good in Russia. The morbidity growth including high morbidity in infants and growing morbidity in children of 7–14 years old reflects active pathogen circulation in population. There is higher mortality from infectious and respiratory diseases in general population and in infants in Russia compared to European countries. Conclusion. The current approach to epidemiological surveillance on pertussis in Russia needs to be improved. Implementation of molecular and other new laboratory methods for pertussis diagnosis could improve identi fication of the infection sources, etiological diagnosis and treatment efficacy. The morbidity of pertussis could be decreased by a wide use of acellular vac cine and additional revaccinations.

1. Rushby J., Miller M., Halsey N.A. Vaccine preventable diseases. In: Jamison D.T., Breman J.G., Measham A.R. et al., eds. Disease control priorities in developing countries. New York: Oxford University Press; 2006: 389–412.

2. Global Health Observatory Data Repository. http://apps. who.int/gho/data/node.main.ChildMortREG100?lang=en; accessed July 2015

3. Zaytsev E.M. Epidemiology and pertussis prevention using vaccination. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2013; 3: 103–105 (in Russian).

4. Ivashinnikova G.A., Borisova O.Yu., Gadua N.T. et al. Characterization of recent B.pertussis strains according to structure of ptxP gene coding pertussis toxin. Infektsionnye bolezni: pril. 2012: 161 (in Russian).

5. Mazurova I.K., Borisova O.Yu., Kombarova S.Yu. et al. Molecular characterization of штаммов Bordetella strains identified in different epidemiological periods. Zhurnal molekulyarnaya genetika, mikrobiologiya i virusologiya. 2005; 4: 21–25 (in Russian).

6. Alekseeva I.A. Provision of pertussis component quality in AKDS vaccine. Infektsiya i immunitet. 2012; 2: 77 (in Russian).

7. Tatochenko V.K., Ozeretskovskiy N.A., Fedorov A.M. Immunoprevention (a reference book). Moscow: Kontinent Press; 2011 (in Russian).

8. Wearing H.J., Rohani P. Estimating the duration of pertus sis using immunity epidemiological signatures. PLoS Pathogens. 2009. DOI: 0.1371/journal.ppat.1000647

9. Druzhinina T.A. Current pertussis epidemiology in Yaroslavl’ region. Infektsionnye bolezni: pril. 2010: 100 (in Russian).

10. Tseneva G.Ya., Kurova N.N. Microbiological characterization of causative pathogen and modern laboratory diagnosis of pertussis (a review). Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2003; 4: 329–341 (in Russian).

11. Bulanova I.A., Titova L.V., Emets O.A. Serological diagnosis of pertussis. Infektsionnye bolezni: pril. 2011: 59 (in Russian).

12. WHO SAGE pertussis working group Background paper SAGE April 2014. http://www.who.int/

13. Heininger U., Stehr K., Cherry J.D. Serious pertussis over looked in infants. Eur. J. Pediatr. 1992; 151: 342–343. http://dx.doi.org/10.1007/BF02113254

14. World Health Organization. 2014. Immunization, vaccines and biologics (pertussis). World Health Organization, Geneva, Switzerland. Accessed 31 January 2015. http://www. who.int/immunization/ monitoring_surveillance/burden/vpd/ surveillance_type/passive/ pertussis/en/

15. Leung A.K., Robson W.L., Davies H.D. Pertussis in adolescent. Adv. Ther. 2007; 24 (2): 353–361.

16. Semenova L.V., Romanenko V.V., Skoryunova T.V. Pertussis monitoring in children of Sverdlovsk region. Infektsiya i immunitet. 2012; 2: 53 (in Russian).

17. Knuf M., Zepp F., Meyer C. et al. Immunogenicity of a single dose of reduced antigen acellular pertussis vaccine in a non vaccinated adolescent population. Vaccine. 2006; 24: 2043–2048. http://dx.doi.org/10.1016/j.vaccine.2005.11.024

18. Thierry Carstensen B., Jordan K., Uhlving H.H. et al. A randomised, double blind, noninferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. Vaccine. 2012; 30: 5464–5471. http://dx.doi.org/10.1016/j.vaccine.2012.06.073

19. Purdy K.W., Hay J.W., Botteman M.F., Ward J.I. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost benefit analysis. Clin. Infect. Dis. 2004; 39: 20–28. http://dx.doi.org/10.1086/421091

20. A leaflet of ADACEL (a combined absorbed vaccine for prevention of diphtheria (with reduced antigen amount), tetanus and pertussis [acellular vaccine]) (in Russian).